Paxlovid, the antiviral pill that reduces the risk of hospitalization and death from Covid-19, also reduces the risk of long Covid, according …
From
To
Covid-19 patients with a history of cardiovascular disease are at an increased risk of developing severe illness and could benefit most from t…
As the coronavirus evolves, the number of treatment options that remain effective against new variants has dwindled. Pfizer's antiviral pill P…
The US Food and Drug Administration revised the emergency use authorization for Pfizer's Covid-19 antiviral treatment, Paxlovid, on Wednesday …
People who have a Covid-19 rebound after treatment with the antiviral drug Paxlovid can be contagious and may not know it because they might n…
Pfizer has begun a Phase 2 and 3 clinical trial of its Covid-19 antiviral treatment, Paxlovid, in children ages 6 to 17, the company said Wedn…
Pfizer's Paxlovid is on the market, and is the first antiviral medication to have significant results for those with COVID-19.
The studies show Paxlovid lowered hospitalizations by 90% and deaths were reduced by 100%.
The antivirals are for those with mild-to-moderate COVID-19 who are at high risk for becoming severely ill, including hospitalization or death.